ABVC

ABVC is, by its own filing, a "clinical stage biopharmaceutical company with operations that generate unsubstantial revenues" — and the numbers confirm it. FY2025 revenue was just $296K against a $7.91M net loss (which actually widened 61% YoY off FY2024's -$4.90M), an operating margin of -2,416%, and a -71% ROE. Four of the last five years show essentially zero revenue and cumulative losses that have piled into a -$76.9M accumulated deficit. This is not a business with a product on the market; every pipeline asset it names — ABV-1701 (Vitargus), ABV-1505 (ADHD), ABV-1601, ABV-1519 — is stuck in Phase I/II, and the company openly states it must find a large-pharma partner to fund Phase III, the NDA, and commercialization for any of them. There is no near-term path to self-sustaining revenue.

The balance sheet is the disqualifier. The company holds just $681K of cash against a -$2.99M annual operating burn — roughly three months of runway on hand — while current liabilities of $6.16M dwarf current assets of $2.50M (a 0.41x current ratio). The only reason stockholders' equity jumped to $11.1M (+806%) and total assets to $21.1M (+179%) is non-cash/financing activity, not operations: the R&D 'company' spent a token $121K on R&D while diluting shareholders by 61.2% in a single year. Continued survival is explicitly contingent on its ability to "raise sufficient funds in the capital markets," which for a micro-cap means more of the same relentless dilution. Note too the 2023 Zhonghui deal — swapping 370,000 shares for a 20% stake in Chinese property still "pending approval from the Chinese government" — which reads as a company using equity for illiquid, non-core assets rather than advancing drugs.